AZD-5363
AZD5363, a novel pyrrolopyrimidine-derived compound, inhibits all AKT isoforms (IC50 30 μM) . (In Vivo) :Oral dosing of Capivasertib (AZD5363) to nude mice causes dose- and time-dependent reduction of PRAS40, GSK3β, and S6 phosphorylation in BT474c xenografts (PRAS40 phosphorylation EC50 ~0.1 μM total plasma exposure), reversible increases in blood glucose concentrations, and dose-dependent decreases in 2[18F]fluoro-2-deoxy-D-glucose (18F-FDG) uptake in U87-MG xenografts. Chronic oral dosing of Capivasertib caused dose-dependent growth inhibition of xenografts derived from various tumor types, including HER2+ breast cancer models. Capivasertib also significantly enhances the antitumor activity of RP-56976 and GW572016 in breast cancer xenografts.
Product Specifications
CAS Number
1143532-39-1
Product Name Alternative
AZD5363 | AZD-5363 | AZD 5363 | Capivasertib
Purity
>98% (HPLC)
Solubility
DMSO: 86 mg/mL (200.5 mM)
Smiles
O=C (C1 (N) CCN (C2=C3C (NC=C3) =NC=N2) CC1) N[C@H] (C4=CC=C (Cl) C=C4) CCO
Molecular Formula
C21H25ClN6O2
Molecular Weight
428.92
Storage Conditions
Storage temperature: -20°C. Stability: ≥ 2 years
Notes
For research use only.
Other Product Names
(S) -4-amino-N- (1- (4-chlorophenyl) -3-hydroxypropyl) -1- (7H-pyrrolo[2,3-d]pyrimidin-4-yl) piperidine-4-carboxamide
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
